Filing Flows › Immunocore Holdings (IMCR) › Q2 2026
Immunocore Holdings (IMCR) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 6, 2026
Immunocore Holdings (IMCR) reported revenue of $116M for the second quarter 2026 (Q2 2026), +18% from a year earlier and +9% from the quarter before. Operating margin was -2.6%, net loss $808K (0.7% of revenue).
Immunocore Holdings, Q2 2026: revenue $116M (+18% year over year), operating margin -2.6%, net loss $808K, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $116M | +9% | +18% |
| Operating profit | −$3.0M | -141% | — |
| Net earnings | −$808K | -106% | — |
| Operating cash flow | $15.9M | — | -39% |
| Free cash flow | $15.1M | — | -41% |
What changed
Revenue was $115.9M in Q2 2026, up 18% year over year and up 9% from the previous quarter.
Operating costs exceeded revenue by $3.0M, an operating margin of -2.6%. Total costs grew 5% against revenue growth of 18%. The quarter ended with a net loss of $808K, after a profit of $13.0M the previous quarter. Non-operating items added $2.5M, -483% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $15.9M (down 39% year over year). Non-cash charges added back $1.0M of depreciation and $9.4M of share-based compensation. Working capital and other items added $6.3M. Capital expenditures of $786K left free cash flow of $15.1M.
Questions
What was Immunocore Holdings' revenue in the second quarter 2026?
Immunocore Holdings (IMCR) reported revenue of $116M for the second quarter 2026 (Q2 2026), +18% from a year earlier and +9% from the quarter before.
Was Immunocore Holdings profitable in the second quarter 2026?
Operating loss was $3.0M (-2.6% of revenue) and net loss $808K.